
Cosibelimab received an NCCN Category 2A preferred designation for locally advanced CSCC, supported by durable responses and low immune toxicity.
References for: Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer
over 8 years ago
Medical World News: Clinical/Managed Care Updatesover 8 years ago
Medical World News: Clinical Updatesover 8 years ago
Medical World News: Regulatory Updates